Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

FULCFulcrum Therapeutics, Inc.

Nasdaq · CIK 0001680581
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts212

Identity from submissions API

NameFulcrum Therapeutics, Inc.
CIK0001680581
TickersFULC
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN474839948
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone617-651-8851
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
MA
Mailing address
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

527 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128728 005-91080 261563803 34 14560
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000935836-26-000588 005-91080 261559310 34 15696
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-127211 005-91080 261553886 34 11110
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-007765 005-91080 261552307 34 16770
2026-11-12 10-Q 10-Q 0001193125-26-458453 001-38978 261547208 34 9505244 1 1
2026-11-12 425 425 0001193125-26-458402 001-38978 261547058 34 30112
2026-11-12 8-K 8-K 8.01 0001193125-26-458387 001-38978 261547021 34 150756 1 1
2026-11-04 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-003437 333-298705 261524410 33 1718
2026-11-04 424B3 424B3 0001193125-26-447368 333-298705 261522757 33 7826305
2026-11-03 S-4/A S-4/A 0001193125-26-444432 333-298705 261514462 33 7895301
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000532 005-91080 261494980 34 171387
2026-10-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002052113-26-001118 005-91080 261490522 34 10901
2026-10-20 S-4/A S-4/A 0001193125-26-426840 333-298705 261473577 33 8247414
2026-10-08 S-4/A S-4/A 0001193125-26-418056 333-298705 261450518 33 7928549
2026-09-02 144 xsl144X01/primary_doc.xml 0001193125-26-379476 001-38978 261352848 33 7954
2026-09-02 S-4 S-4 0001193125-26-379106 333-298705 261352507 33 21938358 1 1
2026-08-17 425 425 0001193125-26-354107 001-38978 261286950 34 155376
2026-08-17 425 425 0001193125-26-353282 001-38978 261284929 34 31109
2026-08-17 425 425 0001193125-26-353280 001-38978 261284925 34 15540059
2026-08-17 8-K 8-K 1.01,3.02,5.01,5.02,7.01,9.01 0001193125-26-353278 001-38978 261284911 34 15992961 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-000923 005-91080 261283022 34 12714
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097278 005-91080 261282895 34 10714
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-005528 005-91080 261282219 34 16910
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-352345 005-91080 261282161 34 12559
2026-08-10 8-K 8-K 5.02 0001193125-26-341385 001-38978 261256395 34 148250 1 1
2026-08-03 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000070858-26-000396 005-91080 261231372 34 171237
2026-07-30 10-Q 10-Q 0001193125-26-326098 001-38978 261223271 34 9969965 1 1
2026-07-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002576 005-91080 261212598 34 10837
2026-07-20 4 xslF345X06/form4-07212026_010750.xml 0001178579-26-000016 9415
2026-07-17 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002052113-26-000745 005-91080 261182518 34 10849
2026-07-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-008613 005-91080 261178416 34 14398
2026-07-15 4 xslF345X06/form4-07152026_110717.xml 0001178579-26-000014 12823
2026-07-15 3 xslF345X06/form3-07152026_110708.xml 0001178579-26-000013 6368
2026-07-02 4 4 0001193125-26-294703 5442
2026-07-02 4 4 0001193125-26-294699 5437
2026-07-02 4 4 0001193125-26-294697 5451
2026-07-02 4 4 0001193125-26-294692 5456
2026-07-02 4 4 0001193125-26-294691 5452
2026-07-02 4 4 0001193125-26-294690 5456
2026-07-02 4 4 0001193125-26-294683 5382
2026-07-02 4 4 0001193125-26-294680 5451
2026-06-30 4 4 0001193125-26-290622 5283
2026-06-26 144 xsl144X01/primary_doc.xml 0001950047-26-006549 001-38978 261129778 33 4725
2026-06-25 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000935836-26-000331 005-91080 261123366 34 15798
2026-06-25 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000935836-26-000330 005-91080 261123311 34 15798
2026-06-25 8-K 8-K 5.07 0001193125-26-282873 001-38978 261122388 34 145866 1 1
2026-06-11 8-K 8-K 5.02 0001193125-26-267659 001-38978 261083512 34 153361 1 1
2026-06-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001214659-26-007338 005-91080 261080932 34 27487
2026-06-04 8-K 8-K 2.05,8.01 0001193125-26-257376 001-38978 261064889 34 157683 1 1
2026-06-01 8-K 8-K 8.01,9.01 0001193125-26-251394 001-38978 261050668 34 251343 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062675 005-91080 26988792 34 10907
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-226891 005-91080 26988271 34 12846
2026-05-01 4 4 0001193125-26-201468 5346
2026-05-01 3 3 0001193125-26-201437 17799
2026-04-30 DEFA14A DEFA14A 0001193125-26-197308 001-38978 26925467 34 1755161
2026-04-30 ARS ARS 0001193125-26-197291 001-38978 26925408 34 1142156
2026-04-30 DEF 14A DEF 14A 0001193125-26-197196 001-38978 26925151 34 11392187 1 1
2026-04-27 10-Q 10-Q 0001193125-26-178814 001-38978 26896483 34 8646183 1 1
2026-04-27 8-K 8-K 1.02,2.02,5.02,9.01 0001193125-26-178806 001-38978 26896472 34 343396 1 1
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001344 005-91080 26800240 34 7089
2026-02-24 S-8 S-8 0001193125-26-065206 333-293670 26667509 33 184000 1 1
2026-02-24 10-K 10-K 0001193125-26-065197 001-38978 26667450 34 12322448 1 1
2026-02-24 8-K 8-K 2.02,9.01 0001193125-26-065190 001-38978 26667435 34 367135 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-26-000043 005-91080 26642098 34 15443
2026-02-04 4/A 4/A 0001193125-26-037606 5357
2026-02-04 4 4 0001193125-26-037576 5315
2026-02-04 4 4 0001193125-26-037574 5312
2026-02-04 4 4 0001193125-26-037573 5148
2026-02-04 4 4 0001193125-26-037575 5332
2026-02-04 4 4 0001193125-26-037572 5410
2026-01-12 8-K 8-K 2.02,7.01,9.01 0001193125-26-009845 001-38978 26524787 34 15722726 1 1
2026-01-06 4 4 0001193125-26-004572 5148
2025-12-17 4 4 0001193125-25-322740 4768
2025-12-15 144 xsl144X01/primary_doc.xml 0001950047-25-010350 001-38978 251572052 33 4884
2025-12-11 8-K 8-K 1.01,8.01,9.01 0001193125-25-314728 001-38978 251563349 34 1093561 1 1
2025-12-11 424B5 424B5 0001193125-25-314724 333-277419 251563347 33 578438
2025-12-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-25-000068 005-91080 251562498 34 14878
2025-12-10 4 xslF345X05/form4-12102025_091221.xml 0001231919-25-000596 15141
2025-12-10 FWP FWP 0001193125-25-313415 333-277419 251560765 34 118218
2025-12-08 144 xsl144X01/primary_doc.xml 0001178937-25-000086 001-38978 251557093 33 5603
2025-12-08 424B5 424B5 0001193125-25-311359 333-277419 251556753 33 503929
2025-12-08 8-K 8-K 7.01,8.01,9.01 0001193125-25-310509 001-38978 251554569 34 17730860 1 1
2025-11-21 4 4 0001193125-25-291392 5148
2025-11-19 144 xsl144X01/primary_doc.xml 0001950047-25-009089 001-38978 251499602 33 4720
2025-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004883 005-91080 251475731 34 12391
2025-10-29 10-Q 10-Q 0001193125-25-254633 001-38978 251426805 34 10416099 1 1
2025-10-29 8-K 8-K 2.02,9.01 0001193125-25-254619 001-38978 251426791 34 376283 1 1
2025-10-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-002864 005-91080 251401977 34 10747
2025-08-28 8-K 8-K 7.01,9.01 0001193125-25-190746 001-38978 251268808 34 15532036 1 1
2025-08-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-003497 005-91080 251204320 34 12321
2025-07-29 10-Q 10-Q 0000950170-25-099407 001-38978 251157787 34 10089530 1 1
2025-07-29 8-K 8-K 2.02,8.01,9.01 0000950170-25-099404 001-38978 251157774 34 16793735 1 1
2025-06-30 4 4 0000950170-25-091584 5319
2025-06-30 4 4 0000950170-25-091583 5300
2025-06-30 4 4 0000950170-25-091582 5316
2025-06-30 4 4 0000950170-25-091585 5312
2025-06-30 4 4 0000950170-25-091580 5245
2025-06-30 4 4 0000950170-25-091579 5305
2025-06-30 4 4 0000950170-25-091578 5311
2025-06-30 4 4 0000950170-25-091577 5314
2025-06-27 8-K 8-K 5.07 0001193125-25-151276 001-38978 251086452 34 148958 1 1
2025-05-09 4 4 0000950170-25-068038 5032
2025-05-07 DEFR14A DEFR14A 0000950170-25-065795 001-38978 25922079 34 3870701
2025-05-02 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-002740 005-91080 25910222 34 16958
2025-05-01 10-Q 10-Q 0000950170-25-061442 001-38978 25899375 34 8995273 1 1
2025-05-01 8-K 8-K 2.02,9.01 0000950170-25-061439 001-38978 25899356 34 331350 1 1
2025-04-30 ARS ARS 0000950170-25-061020 001-38978 25894829 34 4742888
2025-04-30 DEFA14A DEFA14A 0000950170-25-061013 001-38978 25894784 34 1825937
2025-04-30 DEF 14A DEF 14A 0000950170-25-061000 001-38978 25894715 34 3076087 1 1
2025-04-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001576419-25-000745 005-91080 25844710 34 10746
2025-03-04 8-K 8-K 1.02 0000950170-25-032355 001-38978 25705882 34 185832 1 1
2025-02-25 S-8 S-8 0001193125-25-034249 333-285180 25659398 33 72451
2025-02-25 10-K 10-K 0000950170-25-026068 001-38978 25659378 34 13734550 1 1
2025-02-25 8-K 8-K 2.02,9.01 0000950170-25-026063 001-38978 25659341 34 370715 1 1
2025-02-12 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-000860 005-91080 25612605 34 15610
2025-01-28 4 4 0000950170-25-009818 5315
2025-01-28 4 4 0000950170-25-009816 5413
2025-01-28 4 4 0000950170-25-009815 5335
2025-01-28 4 4 0000950170-25-009813 5318
2025-01-13 8-K 8-K 2.02,7.01,9.01 0001193125-25-004942 001-38978 25524738 34 8225914 1 1
2025-01-06 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-000110 005-91080 25511961 34 16342
2024-12-23 8-K 8-K 1.02,9.01 0001193125-24-284214 001-38978 241574072 34 151330 1 1
2024-12-06 SC 13G us3596161097_120624.txt 0002012383-24-004535 005-91080 241532638 34 13777
2024-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-24-119151 005-91080 241463827 34 10602
2024-11-14 SC 13G/A d11527936_13g-a.htm 0000919574-24-006744 005-91080 241462919 34 123655
2024-11-14 4 4 0000950170-24-127074 5197
2024-11-14 3 3 0000950170-24-127055 13876
2024-11-14 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-24-006487 005-91080 241456863 34 63180
2024-11-13 10-Q 10-Q 0000950170-24-125931 001-38978 241451151 34 8941310 1 1
2024-11-13 8-K 8-K 2.02,9.01 0000950170-24-125927 001-38978 241451137 34 305044 1 1
2024-11-12 8-K 8-K 5.02 0001193125-24-256101 001-38978 241449954 34 146411 1 1
2024-11-12 SC 13G/A UnitedStates_13G__FulcrumThe.txt 0000932471-24-001033 005-91080 241447583 34 6514
2024-11-08 SC 13G us3596161097_110824.txt 0002012383-24-003431 005-91080 241439575 34 13775
2024-11-04 SC 13G/A UnitedStates_13G__FulcrumThe.txt 0000932471-24-000432 005-91080 241421704 34 5574
2024-10-21 SC 13G us3596161097_102124.txt 0002012383-24-000922 005-91080 241383510 34 13763
2024-10-07 SC 13G/A filing.txt 0000315066-24-002025 005-91080 241356679 34 8238
2024-09-24 8-K 8-K 2.05,9.01 0000950170-24-109069 001-38978 241320217 34 175980 1 1
2024-09-23 3 xslF345X02/form3-09232024_080926.xml 0001415889-24-023836 11524
2024-09-20 SC 13G SC 13G 0001193125-24-222915 005-91080 241313656 34 78227
2024-09-16 SC 13G/A SC 13G/A 0001104659-24-100319 005-91080 241302306 34 82784
2024-09-12 8-K 8-K 8.01,9.01 0001193125-24-217822 001-38978 241294410 34 182388 1 1
2024-08-23 SC 13G/A SC 13G/A 0001104659-24-092442 005-91080 241236550 34 95421
2024-08-23 4 xslF345X05/form4-08232024_040801.xml 0001415889-24-022127 13794
2024-08-22 8-K 8-K 3.02,9.01 0001193125-24-205347 001-38978 241231971 34 242842 1 1
2024-07-31 S-8 S-8 0001193125-24-189503 333-281119 241159925 33 65830
2024-07-31 10-Q 10-Q 0000950170-24-088238 001-38978 241159878 34 10358808 1 1
2024-07-31 8-K 8-K 2.02,9.01 0000950170-24-088236 001-38978 241159867 34 305402 1 1
2024-07-08 4 4 0000950170-24-081949 7175
2024-06-18 4 4 0000950170-24-074892 5321
2024-06-18 4 4 0000950170-24-074888 5321
2024-06-18 4 4 0000950170-24-074887 5326
2024-06-18 4 4 0000950170-24-074885 5326
2024-06-18 4 4 0000950170-24-074884 5307
2024-06-18 4 4 0000950170-24-074883 5327
2024-06-18 4 4 0000950170-24-074882 5313
2024-06-18 4 4 0000950170-24-074868 5124
2024-06-18 3 3 0000950170-24-074855 14777
2024-06-17 8-K 8-K 5.02,5.07 0001193125-24-162653 001-38978 241048839 34 158150 1 1
2024-05-13 10-Q 10-Q 0000950170-24-058193 001-38978 24936860 34 7746832 1 1
2024-05-13 8-K 8-K 1.01,2.02,9.01 0000950170-24-058187 001-38978 24936843 34 266881 1 1
2024-05-09 4 4 0000950170-24-056947 4864
2024-04-25 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-25 16:30:00 9999999995-24-001122 333-277419 24878366 33 1724
2024-04-24 CORRESP filename1.htm 0001193125-24-110274 5068
2024-04-19 ARS ARS 0001193125-24-102886 001-38978 24857877 34 5956320
2024-04-19 DEFA14A DEFA14A 0001193125-24-102877 001-38978 24857820 34 515653
2024-04-19 DEF 14A DEF 14A 0001193125-24-102863 001-38978 24857732 34 1073956
2024-03-20 4 4 0000950170-24-034177 5497
2024-03-20 3 3 0000950170-24-034165 14341
2024-03-08 4 4 0000950170-24-028827 5143
2024-03-08 144 xsl144X01/primary_doc.xml 0000950170-24-028824 001-38978 24735978 33 4580
2024-03-05 4 4 0000950170-24-025933 5061
2024-03-01 UPLOAD filename1.pdf 0000000000-24-002379 333-277419 40299
2024-02-27 S-8 S-8 0001193125-24-048113 333-277421 24688575 33 79688
2024-02-27 S-3 S-3 0001193125-24-048095 333-277419 24688389 33 1334349
2024-02-27 10-K 10-K 0000950170-24-021074 001-38978 24686353 34 11347446 1 1
2024-02-27 8-K 8-K 2.02,9.01 0000950170-24-020615 001-38978 24681914 34 274911 1 1
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023996 005-91080 24640161 34 80465
2024-02-14 SC 13G/A SC 13G/A 0001193125-24-036266 005-91080 24638636 34 143609
2024-02-14 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-24-001576 005-91080 24632394 34 65054
2024-02-13 SC 13G/A d10963156_13g-a.htm 0000919574-24-000953 005-91080 24623844 34 121153
2024-02-09 SC 13G/A filing.txt 0000315066-24-001144 005-91080 24611655 34 8140
2024-02-07 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-24-001172 005-91080 24602192 34 101374
2024-01-30 4 4 0000950170-24-009096 7640
2024-01-30 4 4 0000950170-24-009094 5318
2024-01-30 4 4 0000950170-24-009092 5321
2024-01-19 4 4 0000950170-24-005790 5624
2023-11-07 10-Q 10-Q 0000950170-23-059755 001-38978 231381517 34 10479287 1 1
2023-11-07 8-K 8-K 2.02,9.01 0000950170-23-059753 001-38978 231381503 34 315325 1 1
2023-10-02 8-K 8-K 5.02 0001193125-23-249011 001-38978 231299558 34 142421 1 1
2023-08-22 8-K 8-K 7.01,9.01 0001193125-23-217439 001-38978 231190956 34 5112430 1 1
2023-08-09 4 4 0000950170-23-040615 5382
2023-08-09 3 3 0000950170-23-040592 14143
2023-08-03 10-Q 10-Q 0000950170-23-037579 001-38978 231138035 34 10628891 1 1
2023-08-03 8-K 8-K 2.02,5.02,9.01 0000950170-23-037574 001-38978 231138012 34 359157 1 1
2023-07-10 8-K 8-K 1.01 0001193125-23-184748 001-38978 231080489 34 155225 1 1
2023-07-07 SC 13G/A us3596161097_070723.txt 0001306550-23-009506 005-91080 231077205 34 12336
2023-07-03 3 3 0000950170-23-031405 15140
2023-06-29 4 4 0000950170-23-030765 5244
2023-06-29 4 4 0000950170-23-030757 5302
2023-06-29 4 4 0000950170-23-030758 5231
2023-06-29 4 4 0000950170-23-030756 5218
2023-06-29 4 4 0000950170-23-030755 5239
2023-06-29 4 4 0000950170-23-030753 5304
2023-06-29 4 4 0000950170-23-030752 5245
2023-06-26 10-K/A 10-K/A 0000950170-23-029693 001-38978 231038895 34 11202984 1 1
2023-06-26 10-K/A 10-K/A 0000950170-23-029689 001-38978 231038871 34 9894278 1 1
2023-06-23 10-K/A 10-K/A 0000950170-23-029682 001-38978 231038837 34 9714088 1 1
2023-06-09 8-K 8-K 5.03,5.07,9.01 0001193125-23-164435 001-38978 231005255 34 200713 1 1
2023-05-15 10-Q 10-Q 0000950170-23-021960 001-38978 23918353 34 9252902 1 1
2023-05-15 8-K 8-K 2.02,5.02,9.01 0000950170-23-021958 001-38978 23918346 34 326651 1 1
2023-05-11 4 4 0000950170-23-021245 4782
2023-04-28 4 4 0000950170-23-015832 5625
2023-04-28 ARS ARS 0001193125-23-126993 001-38978 23866451 34 5985937
2023-04-28 4 4 0000950170-23-015824 5568
2023-04-28 DEFA14A DEFA14A 0001193125-23-126931 001-38978 23866138 34 421930
2023-04-28 DEF 14A DEF 14A 0001193125-23-126856 001-38978 23865739 34 948648
2023-04-18 PRE 14A PRE 14A 0001193125-23-104980 001-38978 23826866 34 917622
2023-04-05 8-K 8-K 5.02 0001193125-23-091620 001-38978 23801228 34 144602 1 1
2023-03-09 S-8 S-8 0001193125-23-065374 333-270385 23718277 33 69154
2023-03-09 10-K 10-K 0000950170-23-006841 001-38978 23718180 34 15441158 1 1
2023-03-09 8-K 8-K 2.02,9.01 0000950170-23-006834 001-38978 23718162 34 377967 1 1
2023-03-06 SC 13G FULCRUM THERAPEUTICS, INC. 0000902664-23-002133 005-91080 23709455 34 109181
2023-02-14 SC 13G/A SCHEDULE 13G/A, AMENDMENT #1 0000899140-23-000389 005-91080 23629493 34 60621
2023-02-14 SC 13G/A SC 13G/A 0001193125-23-039067 005-91080 23629062 34 153868
2023-02-14 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-23-001712 005-91080 23623819 34 63918
2023-02-13 4 FORM 4 SUBMISSION 0000899243-23-004745 5436
2023-02-13 4 FORM 4 SUBMISSION 0000899243-23-004744 5438
2023-02-13 4 FORM 4 SUBMISSION 0000899243-23-004743 5493
2023-02-13 4 FORM 4 SUBMISSION 0000899243-23-004742 5443
2023-02-13 SC 13G/A d9928609_13g-a.htm 0000919574-23-000956 005-91080 23615407 34 108285
2023-02-09 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-23-001349 005-91080 23604681 34 101812
2023-02-09 SC 13G/A filing.txt 0000315066-23-001651 005-91080 23602238 34 8061
2023-02-01 SC 13G/A us3596161097_020123.txt 0001306550-23-006387 005-91080 23577465 34 13266
2023-01-24 4 OWNERSHIP DOCUMENT 0001104659-23-006213 10407
2023-01-23 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-23-000296 005-91080 23544096 34 27192
2023-01-18 8-K 8-K 1.01,8.01,9.01 0001193125-23-010273 001-38978 23535109 34 410511 1 1
2023-01-18 424B5 424B5 0001193125-23-010269 333-260754 23535087 33 791168
2023-01-17 424B5 424B5 0001193125-23-009584 333-260754 23532312 33 796093
2023-01-17 8-K 8-K 2.02,8.01,9.01 0001193125-23-009500 001-38978 23532050 34 166184 1 1
2023-01-13 4 FORM 4 SUBMISSION 0000899243-23-001803 4765
2023-01-06 4 OWNERSHIP DOCUMENT 0001104659-23-001881 13313
2023-01-06 SC 13G/A SC 13G/A 0001104659-23-001871 005-91080 23515464 34 73180
2023-01-04 8-K 8-K 2.02,5.02,8.01,9.01 0001193125-23-001193 001-38978 23504345 34 6277246 1 1
2022-12-29 4 OWNERSHIP DOCUMENT 0001104659-22-130982 10970
2022-12-21 4 OWNERSHIP DOCUMENT 0001104659-22-129121 10967
2022-12-16 4 OWNERSHIP DOCUMENT 0001104659-22-127883 15121
2022-12-15 4 FORM 4 SUBMISSION 0000899243-22-038602 13220
2022-11-09 4 FORM 4 SUBMISSION 0000899243-22-035434 5602
2022-11-09 3 FORM 3 SUBMISSION 0000899243-22-035433 8242
2022-11-08 10-Q 10-Q 0000950170-22-022913 001-38978 221367287 34 11733791 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-022910 001-38978 221367264 34 370095 1 1
2022-10-19 8-K 8-K 5.02 0001193125-22-265260 001-38978 221318704 34 142069 1 1
2022-08-26 3 OWNERSHIP DOCUMENT 0001104659-22-095159 9480
2022-08-26 SC 13G FULCRUM THERAPEUTICS, INC. 0001104659-22-095158 005-91080 221205768 34 74102
2022-08-23 8-K 8-K 8.01 0001193125-22-227590 001-38978 221188169 34 143665 1 1
2022-08-17 8-K 8-K 1.01,8.01,9.01 0001193125-22-222443 001-38978 221171488 34 431015 1 1
2022-08-17 424B5 424B5 0001193125-22-222439 333-260754 221171440 33 586339
2022-08-15 424B5 424B5 0001193125-22-221378 333-260754 221167515 33 590098
2022-08-11 4 FORM 4 SUBMISSION 0000899243-22-028370 5598
2022-08-11 4 FORM 4 SUBMISSION 0000899243-22-028368 5537
2022-08-11 3 FORM 3 SUBMISSION 0000899243-22-028366 11121
2022-08-11 10-Q 10-Q 0000950170-22-016644 001-38978 221153704 34 10690731 1 1
2022-08-11 8-K 8-K 5.02,9.01 0001193125-22-217954 001-38978 221153637 34 222841 1 1
2022-08-11 8-K 8-K 2.02,2.05,9.01 0000950170-22-016633 001-38978 221153617 34 354591 1 1
2022-07-19 4 FORM 4 SUBMISSION 0000899243-22-026322 10049
2022-07-11 8-K 8-K 5.02 0001193125-22-191340 001-38978 221077538 34 144191 1 1
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024528 12415
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024525 10088
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024524 10100
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024527 5438
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024526 10069
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024523 10069
2022-06-29 4 FORM 4 SUBMISSION 0000899243-22-024522 10098
2022-06-22 SC 13G SCHEDULE 13G 0000899140-22-000569 005-91080 221032222 34 67527
2022-06-10 8-K 8-K 8.01 0001193125-22-171957 001-38978 221009077 34 160817 1 1
2022-06-09 8-K 8-K 5.07 0001193125-22-171026 001-38978 221006017 34 152996 1 1
2022-06-08 4 FORM 4 SUBMISSION 0000899243-22-021530 9688
2022-06-06 4 FORM 4 SUBMISSION 0000899243-22-021250 26140
2022-06-06 8-K 8-K 1.02 0001193125-22-168375 001-38978 22998458 34 147012 1 1
2022-05-10 4 FORM 4 SUBMISSION 0000899243-22-017416 7560
2022-05-10 8-K 8-K 1.01,9.01 0001193125-22-145361 001-38978 22907141 34 379246 1 1
2022-05-10 424B5 424B5 0001193125-22-145358 333-260754 22907139 33 409896
2022-05-09 POS EX POS EX 0001193125-22-145085 333-260754 22905837 33 32668
2022-05-09 10-Q 10-Q 0000950170-22-008235 001-38978 22903227 34 9803577 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008232 001-38978 22903205 34 295613 1 1
2022-04-28 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-22-063655,2022-04-28 9999999995-22-001133 333-260754 22869763 33 1688
2022-04-28 DEFA14A DEFA14A 0001193125-22-127540 001-38978 22866544 34 387443
2022-04-28 DEF 14A DEF 14A 0001193125-22-127507 001-38978 22866405 34 1447238
2022-04-11 4 FORM 4 SUBMISSION 0000899243-22-014438 9271
2022-04-05 4 FORM 4 SUBMISSION 0000899243-22-013881 21098
2022-03-14 3 FORM 3 SUBMISSION 0000899243-22-010854 11376
2022-03-10 8-K 8-K 5.02 0001193125-22-072011 001-38978 22729521 34 144315 1 1
2022-03-10 SC 13G FULCRUM THERAPEUTICS, INC. 0000902664-22-002084 005-91080 22729456 34 107783
2022-03-09 SC 13G COWEN FINANCIAL PRODUCTS LLC 0001085146-22-001221 005-91080 22724138 34 27122
2022-03-03 POS AM POS AM 0001193125-22-063655 333-260754 22706769 33 386533
2022-03-03 S-8 S-8 0001193125-22-063643 333-263249 22706756 33 93276
2022-03-03 10-K 10-K 0000950170-22-002727 001-38978 22706727 34 13467653 1 1
2022-03-03 8-K 8-K 2.02,9.01 0000950170-22-002726 001-38978 22706714 34 343861 1 1
2022-03-03 POSASR POSASR 0001193125-22-063344 333-260754 22706436 33 512458
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-042150 005-91080 22634414 34 197761
2022-02-14 SC 13G/A FULCRUM THERAPEUTICS, INC. 0000902664-22-001590 005-91080 22625534 34 60993
2022-02-11 SC 13G/A d9172507_13g-a.htm 0000919574-22-000896 005-91080 22621277 34 107755
2022-02-09 SC 13G/A filing.txt 0000315066-22-001008 005-91080 22604309 34 8348
2022-02-04 SC 13G us3596161097_020422.txt 0000834237-22-007149 005-91080 22593408 34 13227
2022-01-27 S-8 S-8 0001193125-22-018556 333-262356 22559350 33 77407
2022-01-21 4 FORM 4 SUBMISSION 0000899243-22-002881 5400
2022-01-21 4 FORM 4 SUBMISSION 0000899243-22-002880 5459
2022-01-21 4 FORM 4 SUBMISSION 0000899243-22-002879 5452
2022-01-21 4 FORM 4 SUBMISSION 0000899243-22-002878 5448
2022-01-21 4 FORM 4 SUBMISSION 0000899243-22-002877 5385
2022-01-10 4 FORM 4 SUBMISSION 0000899243-22-001475 5545
2022-01-10 3 FORM 3 SUBMISSION 0000899243-22-001471 8158
2022-01-10 8-K 8-K 2.02,5.02,8.01,9.01 0001193125-22-005038 001-38978 22519657 34 197034 1 1
2022-01-07 5 FORM 5 SUBMISSION 0000899243-22-001356 4797
2022-01-04 8-K 8-K 5.02,9.01 0001193125-22-001760 001-38978 22506726 34 179234 1 1
2021-12-09 4 FORM 4 SUBMISSION 0000899243-21-047542 5303
2021-12-09 3 FORM 3 SUBMISSION 0000899243-21-047522 8057
2021-12-06 8-K 8-K 8.01 0001193125-21-348354 001-38978 211471922 34 189654 1 1
2021-11-17 8-K 8-K 5.02,9.01 0001193125-21-331947 001-38978 211418464 34 176126 1 1
2021-11-12 4 FORM 4 SUBMISSION 0000899243-21-044427 9157
2021-11-12 4 FORM 4 SUBMISSION 0000899243-21-044424 15506
2021-11-04 S-3ASR S-3ASR 0001193125-21-319344 333-260754 211378054 33 1368335
2021-11-04 10-Q 10-Q 0001564590-21-054234 001-38978 211377986 34 9730145 1 1
2021-11-04 8-K 8-K 2.02,9.01 0001564590-21-054229 001-38978 211377958 34 336398 1 1
2021-09-27 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-21-009633 005-91080 211278864 34 24889
2021-09-24 4 FORM 4 SUBMISSION 0000899243-21-037615 9155
2021-09-24 4 FORM 4 SUBMISSION 0000899243-21-037614 15504
2021-09-10 SC 13G/A filing.txt 0000315066-21-001729 005-91080 211246042 34 8349
2021-08-12 8-K 8-K 1.01,8.01,9.01 0001193125-21-244795 001-38978 211168256 34 406272 1 1
2021-08-12 424B5 424B5 0001193125-21-244789 333-244136 211168219 33 543751
2021-08-12 4 FORM 4 SUBMISSION 0000899243-21-032755 14441
2021-08-12 4 FORM 4 SUBMISSION 0000899243-21-032753 14331
2021-08-11 S-3MEF S-3MEF 0001193125-21-243764 333-258740 211165385 33 61231
2021-08-11 424B5 424B5 0001193125-21-242235 333-244136 211161587 33 546008
2021-08-10 SC 13G d8918002_13g.htm 0000919574-21-004966 005-91080 211160928 34 123988
2021-08-10 10-Q 10-Q 0001564590-21-042876 001-38978 211158402 34 9421095 1 1
2021-08-10 8-K 8-K 2.02,9.01 0001564590-21-042873 001-38978 211158392 34 186688
2021-06-29 4 FORM 4 SUBMISSION 0000899243-21-026557 4552
2021-06-29 4 FORM 4 SUBMISSION 0000899243-21-026556 4489
2021-06-29 4 FORM 4 SUBMISSION 0000899243-21-026555 4747
2021-06-29 4 FORM 4 SUBMISSION 0000899243-21-026552 4478
2021-06-24 8-K 8-K 8.01 0001193125-21-198675 001-38978 211043018 34 35023
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023287 10034
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023288 10085
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023285 10068
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023286 5437
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023283 10076
2021-06-11 4 FORM 4 SUBMISSION 0000899243-21-023282 10051
2021-06-11 8-K 8-K 5.07 0001193125-21-188915 001-38978 211011698 34 23632
2021-05-12 4 FORM 4 SUBMISSION 0000899243-21-019264 5601
2021-05-12 3 FORM 3 SUBMISSION 0000899243-21-019259 8351
2021-05-06 10-Q 10-Q 0001564590-21-024505 001-38978 21895740 34 7804856 1
2021-05-06 8-K 8-K 2.02,9.01 0001564590-21-024502 001-38978 21895726 34 151553
2021-04-29 DEFA14A DEFA14A 0001193125-21-138560 001-38978 21867412 34 397821
2021-04-29 DEF 14A DEF 14A 0001193125-21-138549 001-38978 21867395 34 791845
2021-04-02 4 FORM 4 SUBMISSION 0000899243-21-014592 10077
2021-04-02 4 FORM 4 SUBMISSION 0000899243-21-014591 5611
2021-04-02 3 FORM 3 SUBMISSION 0000899243-21-014578 8263
2021-03-24 8-K 8-K 5.02,9.01 0001193125-21-092672 001-38978 21768536 34 40990
2021-03-22 SEC STAFF LETTER filename1.pdf 9999999997-21-000920 276148
2021-03-17 4 FORM 4 SUBMISSION 0000899243-21-012179 7497
2021-03-04 S-8 S-8 0001193125-21-068461 333-253862 21712567 33 59795
2021-03-04 10-K 10-K 0001564590-21-010715 001-38978 21712550 34 12274266 1
2021-03-04 8-K 8-K 2.02,5.02,9.01 0001193125-21-068440 001-38978 21712542 34 116686
2021-02-24 4 FORM 4 SUBMISSION 0000899243-21-008015 13867
2021-02-22 SEC STAFF LETTER filename1.pdf 9999999997-21-000614 277220
2021-02-18 4 FORM 4 SUBMISSION 0000899243-21-007119 12155
2021-02-16 SC 13G/A SCHEDULE 13G (AMENDMENT #1) 0000899140-21-000296 005-91080 21637021 34 52609
2021-02-16 SC 13G/A SCHEDULE 13G/A 0001104659-21-023348 005-91080 21634325 34 75417
2021-02-12 SC 13G/A form-sc13ga.htm 0001493152-21-003557 005-91080 21623740 34 192098
2021-02-11 SC 13G/A d8789595_13g-a.htm 0000919574-21-000829 005-91080 21617350 34 127183
2021-02-10 4 FORM 4 SUBMISSION 0000899243-21-005666 5404
2021-02-10 3 FORM 3 SUBMISSION 0000899243-21-005661 12536
2021-02-08 SC 13G/A filing.txt 0000315066-21-001009 005-91080 21599554 34 8303
2021-02-04 4 FORM 4 SUBMISSION 0000899243-21-004949 5462
2021-01-27 4 FORM 4 SUBMISSION 0000899243-21-003474 5425
2021-01-27 4 FORM 4 SUBMISSION 0000899243-21-003472 5400
2021-01-25 4 FORM 4 SUBMISSION 0000899243-21-003173 4904
2021-01-22 4 FORM 4 SUBMISSION 0000899243-21-002928 5362
2021-01-20 8-K 8-K 1.01,8.01,9.01 0001193125-21-012403 001-38978 21538814 34 210877
2021-01-20 424B5 424B5 0001193125-21-012394 333-244136 21538774 33 508044
2021-01-19 424B5 424B5 0001193125-21-011456 333-244136 21535618 33 511736
2021-01-19 8-K 8-K 2.02,5.02 0001193125-21-011438 001-38978 21535517 34 19671
2020-12-07 4 FORM 4 SUBMISSION 0000899243-20-032868 5305
2020-12-07 4 FORM 4 SUBMISSION 0000899243-20-032867 5548
2020-12-07 3 FORM 3 SUBMISSION 0000899243-20-032865 3547
2020-11-13 SC 13G formsc13g.htm 0001493152-20-021235 005-91080 201309548 34 197944
2020-11-10 10-Q 10-Q 0001564590-20-052732 001-38978 201299618 34 8549541 1
2020-11-10 8-K 8-K 2.02,9.01 0001564590-20-052728 001-38978 201299596 34 208117
2020-09-18 SC 13G SCHEDULE 13G 0000899140-20-000435 005-91080 201184750 34 63753
2020-09-14 4 FORM 4 SUBMISSION 0000899243-20-024982 6935
2020-08-17 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-08-17 16:00:00 9999999995-20-002175 333-244136 201111625 33 1676
2020-08-13 CORRESP filename1.htm 0001193125-20-219029 7099
2020-08-12 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-20-215674,2020-08-12 9999999995-20-002111 333-239353 201097017 33 1689
2020-08-12 UPLOAD filename1.pdf 0000000000-20-007385 40256
2020-08-11 POS AM POS AM 0001193125-20-215674 333-239353 201091085 33 253005
2020-08-11 S-3 S-3 0001193125-20-215668 333-244136 201091080 33 1498301
2020-08-11 10-Q 10-Q 0001564590-20-039121 001-38978 201091057 34 7710692 1
2020-08-11 8-K 8-K 2.02,9.01 0001564590-20-039117 001-38978 201091042 34 199686
2020-07-23 8-K 8-K 1.01 0001193125-20-197820 001-38978 201043951 34 25579

Latest XBRL company facts

One latest value per concept from companyfacts (212 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 76.38M 2026-11-08 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
dei EntityPublicFloat Entity Public Float USD 296.08M 2025-06-30 2025 FY 10-K 2026-02-24 0001193125-26-065197
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 4.47M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197196
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.64M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197196
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 15,536 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197196
ffd NetFeeAmt NetFeeAmt USD 0.72 2026-09-01 S-4 2026-09-02 0001193125-26-379106
ffd TtlFeeAmt TtlFeeAmt USD 0.72 2026-09-01 S-4 2026-09-02 0001193125-26-379106
ffd TtlOfferingAmt TtlOfferingAmt USD 5,225.1 2026-09-01 S-4 2026-09-02 0001193125-26-379106
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-09-01 S-4 2026-09-02 0001193125-26-379106
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-09-01 S-4 2026-09-02 0001193125-26-379106
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 509,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AccountsReceivableGrossCurrent Accounts Receivable, before Allowance for Credit Loss, Current USD 0 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 2.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 487,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -759,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 953.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.17M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 2.45M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 10.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap Assets Assets USD 310.81M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AssetsCurrent Assets, Current USD 310.80M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 759,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 190.89M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 190.13M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CapitalLeaseObligationsCurrent Capital Lease Obligations, Current USD 0 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 116.41M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 116.41M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 117.50M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -81.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 21.94M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 76.38M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 76.38M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap CommonStockValue Common Stock, Value, Issued USD 76,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -56.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 13.61M 2020-09-30 2020 Q3 10-Q 2020-11-10 0001564590-20-052732
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 5.96M 2020-09-30 2020 Q3 10-Q 2020-11-10 0001564590-20-052732
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 12.00M 2026-06-30 S-4 2026-09-02 0001193125-26-379106
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 190.10M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 0 2020-09-30 2020 Q3 10-Q 2020-11-10 0001564590-20-052732
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 1.85M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 0 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 0 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021074
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 0 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 251,000 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021074
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 2.85M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 78.36M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 1.85M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 27.71M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 1.33M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 8.30M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent USD 0 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 76.51M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap Depreciation Depreciation USD 554,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap DividendIncomeOperatingPaidInCash DividendIncomeOperatingPaidInCash USD 275.00M 2026-08-16 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap Dividends Dividends USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap DividendsCommonStock Dividends, Common Stock USD 0 2015-08-19 2020-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.73 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.64 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008235
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.73 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.003 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap EmployeeBenefitsAndShareBasedCompensation Employee Benefits and Share-based Compensation USD 6.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 340,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 16.40M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap FinancingReceivableReclassificationToHeldForSale Financing Receivable, Reclassification to Held-for-sale USD 900,000 2026-01-01 2026-06-30 S-4 2026-09-02 0001193125-26-379106
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 24.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2022-01-01 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap ImpairmentOfLeasehold Impairment of Leasehold USD 1.30M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 7.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 20.72M 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -15.70M 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD -103,000 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 372,000 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD -908,000 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap IncreaseDecreaseInAccountsAndOtherReceivables Increase (Decrease) in Accounts and Other Receivables USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-02-27 0000950170-24-021074
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -8.37M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026068
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD -529,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -3.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 9.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap InterestReceivable Interest Receivable USD 1.31M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 100,000 2021-01-01 2021-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap LeaseIncentivePayableCurrent Lease Incentive, Payable, Current USD 0 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 17.11M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 4.24M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 2.42M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 2.73M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 2.65M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 2.57M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 2.50M 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 597,000 2021-09-30 2021 Q3 10-Q 2021-11-04 0001564590-21-054234
us-gaap Liabilities Liabilities USD 8.78M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 310.81M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap LiabilitiesCurrent Liabilities, Current USD 8.59M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap MarketableSecurities Marketable Securities USD 190.13M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 0 2019-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 242,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -33.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -48.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -56.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap NetIncomeLossAttributableToParentDiluted Net Income (Loss) Attributable to Parent, Diluted USD -54.55M 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-10-29 0001193125-25-254633
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -70.82M 2020-01-01 2020-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 Noncash or Part Noncash Acquisition, Intangible Assets Acquired USD 25.50M 2019-01-01 2019-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingExpenses Operating Expenses USD 65.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -65.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 900,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 5.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 6.83M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OperatingLossCarryforwardsValuationAllowance Operating Loss Carryforwards, Valuation Allowance USD 112.70M 2024-12-31 2024 FY 10-K 2025-02-25 0000950170-25-026068
us-gaap OtherAssetsCurrent Other Assets, Current USD 69,000 2025-06-30 2025 Q2 10-Q 2025-07-29 0000950170-25-099407
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 9,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -933,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -933,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 126,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 197,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 29,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-05 0001564590-20-008951
us-gaap PaymentsForOperatingActivities Payments for Operating Activities USD 427,000 2022-01-01 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap PaymentsForRestructuring Payments for Restructuring USD 4.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 333,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PaymentsToAcquireIntangibleAssets Payments to Acquire Intangible Assets USD 91,000 2019-01-01 2019-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 179.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 116,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 7.13M 2019-01-01 2019-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 3.17M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 164.20M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 575,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 25.32M 2018-01-01 2018-06-30 2019 Q2 10-Q 2019-08-26 0001564590-19-032952
us-gaap ProceedsFromIssuanceOrSaleOfEquity Proceeds from Issuance or Sale of Equity USD 47,000 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-15 0000950170-23-021960
us-gaap ProceedsFromRepurchaseOfRedeemablePreferredStock Proceeds from (Repurchase of) Redeemable Preferred Stock USD 0 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 16.80M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-11 0001564590-20-039121
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 900,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -56.01M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 1.05M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RepaymentsOfLongTermCapitalLeaseObligations Repayments of Long-term Capital Lease Obligations USD 18,000 2021-01-01 2021-12-31 2021 FY 10-K/A 2023-06-26 0000950170-23-029689
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 29.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 25.59M 2019-01-01 2019-12-31 2020 FY 10-K/A 2023-06-23 0000950170-23-029682
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 1.09M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 1.09M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestructuringAndRelatedCostIncurredCost Restructuring and Related Cost, Incurred Cost USD 4.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.85 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestructuringCharges Restructuring Charges USD 4.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestructuringCosts Restructuring Costs USD 4.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RestructuringCostsAndAssetImpairmentCharges Restructuring Costs and Asset Impairment Charges USD 54,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-022913
us-gaap RestructuringReserve Restructuring Reserve USD 337,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -650.29M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 7.80M 2021-01-01 2021-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-022913
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap SeveranceCosts1 Severance Costs USD 4.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 9.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 13.499 2025-12-31 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 302.03M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.143 2019-07-04 2019-07-05 2019 FY 10-K 2020-03-05 0001564590-20-008951
us-gaap StockIssued1 Stock Issued USD 95,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 11.85M 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 76,718 2022-01-01 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD -165.14M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-05 0001564590-20-008951
us-gaap StockIssuedDuringPeriodValueEmployeeBenefitPlan Stock Issued During Period, Value, Employee Benefit Plan USD 292,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 164.17M 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 0 2026-01-01 2026-03-31 S-4 2026-09-02 0001193125-26-379106
us-gaap StockRepurchasedAndRetiredDuringPeriodShares Stock Repurchased and Retired During Period, Shares shares 9.35M 2024-08-01 2024-08-31 S-4 2026-09-02 0001193125-26-379106
us-gaap TreasuryStockShares Treasury Stock, Shares shares 0 2022-12-31 2022 FY 10-K/A 2023-06-26 0000950170-23-029693
us-gaap TreasuryStockValue Treasury Stock, Value USD 0 2023-06-30 2023 Q1 10-Q 2023-08-03 0000950170-23-037579
us-gaap UnbilledReceivablesCurrent Unbilled Receivables, Current USD 0 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued Unrecognized Tax Benefits, Income Tax Penalties Accrued USD 0 2024-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued Unrecognized Tax Benefits, Interest on Income Taxes Accrued USD 0 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap UnrecognizedTaxBenefitsPeriodIncreaseDecrease Unrecognized Tax Benefits, Period Increase (Decrease) USD 0 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 24.80M 2025-01-01 2025-12-31 S-4 2026-09-02 0001193125-26-379106
us-gaap VariableLeasePayment Variable Lease, Payment USD 800,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 76.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 40.64M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008235
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 76.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458453

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →